MARKET WIREYahoo Finance • 12h ago
What DBV Technologies (DBVT) Said on Its Q3 Earnings CallYahoo Finance report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
Why DBVT Stock dropped -7.77% Today — RQD Quant Desk Flash
$9.49 -7.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $9.34
DBV Technologies S.A. (DBVT) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $647.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on DBVT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DBVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, DBV Technologies S.A. (NASDAQ: DBVT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $9.49 (-7.77% 1D, market cap $647.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DBVT ranks #960 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DBVT compare to AURA and SLBT in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DBVT carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and SLBT (SL Science Holding Limited) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $656.1M). Among the 5-stock peer group, DBVT leads on earnings multiple (N/A) while DBVT leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DBVT?
▼
Per DBVT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001613780), DBV Technologies S.A. generated $5.6M in revenue (+35.8% YoY), -$146.9M in net income, and -$121.7M in free cash flow against $233.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $9.34 (-1.59%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-15.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DBVT)Realized 20D OHLCV Swing Band: ±11.9%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY DBVT SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+6/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (22% of score)
20D Institutional Volume Accumulation (±11.9% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$9.55-6.1% Next Q
31
Q2 (-2Q)Grade E$8.97+11.3% Next Q
28
Q3 (-1Q)Grade E$9.98-4.9% Next Q
26
CurrentGrade E$9.49-11.1% Hist 90D α
23
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DBVT Turnaround Squeeze
While DBVT currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.44) and Max Pain ($9.96) forces dealer call-delta covering toward $27.49.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DBVT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DBVT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DBVT Stock dropped -7.77% Today — RQD Quant Desk Flash
DBV Technologies S.A. (DBVT) dropped -7.77% to $9.49, trading at 5% of its 52-week range ($8.63 – $26.18). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($8.63 – $26.18) with RSI-14 at 49.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.9% around $9.49 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live DBVT Headlines & Catalysts
MARKET WIREmarkets.businessinsider.com • 15h ago
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026markets.businessinsider.com report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 21h ago
DBV Technologies (DBVT) Shares Plunge 11% Amid Liquidity Concerns and Funding PlansGuruFocus report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
DBV Technologies Q3 2026 Earnings Call TranscriptBenzinga report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
DBV had $165.7 million in cash on Sept. 30, but says it will need more funding.Stock Titan report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
$165.7M in cash comes with a going-concern warning at DBV Technologies (DBVT).Stock Titan report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
$165.7M in cash leaves DBV Technologies (DBVT) needing more capital.Stock Titan report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 3d ago
European Equities Traded in the US as American Depositary Receipts Fall in Friday TradingEuropean equities traded in the US as American depositary receipts were down 0.59% to 1,896.05 on th
MARKET WIREBenzinga • 3d ago
Guggenheim Maintains Buy on DBV Technologies, Lowers Price Target to $46Guggenheim analyst Yatin Suneja maintains DBV Technologies (NASDAQ:DBVT) with a Buy and lowers the price target from $51 to $46.
MARKET WIREBenzinga • 4d ago
Citizens Maintains Market Outperform on DBV Technologies, Lowers Price Target to $47Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and lowers the price target from $55 to $47.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DBVT)
- ✓Walkthrough of DBVT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DBVT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.26%▼ DESCENDING CHANNEL
2026-11-02O $10.65H $10.65L $9.49C $9.49VOL 1.03M
RES: $10.58SUP: $7.77SMA50: $11.44SMA200: $16.91
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DBVT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +35.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DBVT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DBVT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DBVT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DBVT)
Health Care Rank #960 of 1016
⚔️ AURA vs DBVT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DBVT vs. AURA, SLBT, CADL, IAM)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, DBV Technologies S.A. (DBVT) ranks #960 by composite RQD confidence (23/100, grade E) and #412 by equity capitalization ($647.0M). Within this direct 5-issuer industry benchmark cohort, DBVT leads on earnings valuation at N/A trailing P/E, while DBVT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with DBVT at 23/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DBVT
ACTIVE
DBV Technologies S.A. | E | 23/100 | — | — | -35.0% | -7.77% | $647.0M | Benchmark Subject |
| AURA Aura Biosciences Inc. | E | 31/100 | — | — | -35.0% | -2.46% | $652.8M | /aura-vs-dbvt → |
| SLBT SL Science Holding Limited | D | 45/100 | — | — | — | +2.56% | $656.1M | /slbt-vs-dbvt → |
| CADL Candel Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.70% | $661.9M | /cadl-vs-dbvt → |
| IAM Iambic Therapeutics Inc. | D | 49/100 | — | — | — | -5.95% | $676.9M | /iam-vs-dbvt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001613780In its most recent audited fiscal period (FY2025, filed 2025-12-31), DBV Technologies S.A. (DBVT) reported GAAP revenue of $5.6M (+35.8% vs. FY2024 revenue of $4.2M , and -64.2% cumulative change since FY2023) , GAAP net income of -$146.9M, operating cash flow of -$121.2M, and free cash flow of -$121.7M (-14.0% YoY). On the balance sheet, DBVT closed FY2025 with $233.7M in total assets against $0 in total debt (Altman Z-Score: 2.37, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $5.6M | -$146.9M | -$121.2M | -$121.7M | $233.7M | — |
| FY2024 (FY) | 2024-12-31 | $4.2M | -$113.9M | -$104.5M | -$106.8M | $65.7M | — |
| FY2023 (FY) | 2023-12-31 | $15.7M | -$72.7M | -$79.7M | -$79.7M | — | — |
3. DBVT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DBVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, DBV Technologies S.A. (NASDAQ: DBVT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $9.49 (-7.77% 1D, market cap $647.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DBVT ranks #960 in composite RQD confidence.
How does DBVT compare to AURA and SLBT in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DBVT carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and SLBT (SL Science Holding Limited) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $656.1M). Among the 5-stock peer group, DBVT leads on earnings multiple (N/A) while DBVT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DBVT?
Per DBVT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001613780), DBV Technologies S.A. generated $5.6M in revenue (+35.8% YoY), -$146.9M in net income, and -$121.7M in free cash flow against $233.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DBVT trading relative to its 50-day, 200-day, and 52-week technical levels?
DBVT last traded at $9.49 (-7.77% on volume of 410,568 shares), positioning the stock -17.05% below its 50-day simple moving average ($11.44) and -43.88% below its 200-day simple moving average ($16.91). Across its 52-week range of $8.63 to $26.18, DBVT sits at the 4.9% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($8.36 to $10.62).
DBVT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DBVT stock moving today?
Why DBVT Stock dropped -7.77% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 23/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
DBVT — DBV Technologies S.A.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:34:13Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, DBVT scores 23 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 6/20 (ROIC -35%; FCF yield -18.81%), Whale 13F Flow scores 5/20, Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit scores 5/20 (Beta 1.0), and Forensic Balance Sheet scores 4/20 (Altman Z 2.37; Piotroski F 3/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are insider conviction and forensic balance-sheet quality, which together signal that the rating's concerns are not limited to a single metric. The cash engine score reflects negative returns on invested capital and negative free-cash-flow yield, meaning the business is currently consuming capital rather than generating it. Any upside case therefore depends on future operating improvement or additional financing rather than on present cash generation. The rating's verdict is a quantitative assessment in the source data and is presented here for educational context, not as personalized advice.
Business
DBV Technologies S.A. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the profile section. The profile describes the company as a Health Care issuer with a market capitalization of $0.6B. The source data does not describe its products, customers, or revenue model. Reported revenue for FY 2025 was $5.6M per the SEC financials, but the source data does not attribute that revenue to specific products or customers.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $5.6M | $-147.1M | $-146.9M | N/A | $-121.7M | $194.2M | N/A |
| FY 2024 | $4.2M | $-116.6M | $-113.9M | N/A | $-106.8M | $32.5M | N/A |
| FY 2023 | $15.7M | $-76.4M | $-72.7M | N/A | $-79.7M | N/A | N/A |
Per the SEC financials, operating and net losses widened across the reported periods, and the operating margin and net margin are each -60% per the market data section. Gross margin is 0% per the same section. The Roarable RQD rating reports ROIC of -35%, an Altman Z-Score of 2.37, and a Piotroski F-Score of 3/9. The Debt/Equity ratio is 0.5 per the rating's forensic pillar. Cash reported for FY 2025 was $194.2M, up from $32.5M in FY 2024, while debt is not available in source data.
Recent Catalysts & News Wire Analysis
The news wire includes several headlines with no body text beyond the source summaries. A headline reports that DBV Technologies will report third-quarter 2026 financial results and a business update on October 28, 2026. A second headline reports that DBV had $165.7 million in cash on Sept. 30 but says it will need more funding. A third headline reports that the shares plunged 11% amid liquidity concerns and funding plans. Several outlets published Q3 earnings-call coverage on the same day. The proprietary signals list in the supply-chain graph is empty, and the supply-chain graph reports no links. Risk watch items from the wire are the funding requirement and the liquidity concerns. All news items are tagged with a YELLOW light.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream suppliers, downstream customers, or sector dependency chains for DBVT. The only sector context available is the Health Care classification and the Biotechnology: Biological Products industry label. Second-order bottlenecks cannot be identified from the supplied data. The funding-need headline is the one news item that bears on second-order financing effects, since a capital raise could affect share count and per-share economics, but the source data does not quantify dilution.
Open Questions
- What is the company's product pipeline and revenue source, since the source data reports revenue but does not describe what generates it?
- How much additional funding is required, on what timeline, and in what form, given the headline that cash will need supplementing?
- What is the total debt balance, since the debt line is listed as N/A across all periods?
- What are the EPS and P/E figures, which are not available in the source data despite reported losses?
- What were the Q3 2026 results reported on October 28, 2026, since the source data includes only coverage headlines and not the figures themselves?
DBVT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for DBV Technologies S.A. (DBVT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 12h ago
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call Yahoo Finance report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE markets.businessinsider.com • 15h ago
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 markets.businessinsider.com report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 21h ago
DBV Technologies (DBVT) Shares Plunge 11% Amid Liquidity Concerns and Funding Plans GuruFocus report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
DBV Technologies Q3 2026 Earnings Call Transcript Benzinga report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
DBV had $165.7 million in cash on Sept. 30, but says it will need more funding. Stock Titan report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
$165.7M in cash comes with a going-concern warning at DBV Technologies (DBVT). Stock Titan report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
$165.7M in cash leaves DBV Technologies (DBVT) needing more capital. Stock Titan report covering DBV Technologies S.A. (DBVT) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo • 3d ago
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading European equities traded in the US as American depositary receipts were down 0.59% to 1,896.05 on th
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
DBVT Bull vs. Bear Conversation Board — What's Your Call at $9.49?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DBVT 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $9.06 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is DBVT (E • RQD 23/100) a Buy at $10.29?
Welcome to the DBVT (DBV Technologies S.A.) Roar Pit. Current RQD Composite is 23/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $8.33 (-19.0%)
Spot @ $10.29 Pump the brakes on DBVT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on DBVT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless DBV Technologies S.A. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $13.07 (+27.0%)
Spot @ $10.29 DBVT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on DBVT, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $10.29 (52-wk range $8.63 - $26.18), any beat on forward guidance forces shorts and underweight funds to chase.